TRANSGENE
BIOTEK LIMITED
INNOVATING. FOR LIFE.

Date: 13th November, 2026

The General Manager
Department of Corporate Services – CRD
BSE LIMITED, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001.

Ref:- Scrip Code : 526139

Subject: Outcome of the Board Meeting held on Friday, 13th November, 2026.

Dear Sir/Madam,

This is with reference to our letter dated 07th November, 2026, intimating the date of the Board Meeting.

Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held on Friday, 13th November, 2026, has considered and approved the following matters:

1) Unaudited Financial Results: Considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended 30th September, 2026. (Copies enclosed).

2) Limited Review Reports: Considered and took on record the Limited Review Reports on the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended 30th September, 2026. (Copies enclosed).

3) Notice of 36th Annual General Meeting: Considered and approved the Notice convening the 36th Annual General Meeting (AGM) of the Company for the financial year 2025-26, along with the related matters.

4) Directors' Report: Considered and approved the Directors' Report along with its annexures for the financial year 2025-26.

5) Date and Time of AGM: Decided to convene the 36th Annual General Meeting of the Company on Wednesday, 30th December, 2026, at 11:00 A.M. (IST) through Video Conferencing (VC) / Other Audio-Visual Means (OAVM).

6) Closure of Register of Members and Share Transfer Books: Approved the closure of the Register of Members and Share Transfer Books of the Company from Thursday, 24th December, 2026, to Wednesday, 30th December, 2026 (both days inclusive).

7) Appointment of Scrutinizer: Appointed Mrs. Geeta Servani, Practising Company Secretary, as the Scrutinizer to scrutinize the remote e-voting process and e-voting during the AGM in a fair and transparent manner.

8) Remote E-voting Schedule: Approved the remote e-voting period, which shall commence on Sunday, 27th December, 2026, at 9:00 A.M. (IST) and conclude on Tuesday, 29th December, 2026, at 5:00 P.M. (IST).

9) Re-appointment of Chairman and Managing Director: Considered and approved the re-appointment of Dr. K. Koteswara Rao (DIN: 07167872) as Chairman and Managing Director of the Company for a further period of one (1) year, subject to the approval of the shareholders of the Company.

The meeting of the Board of Directors commenced at 11:00 A.M. (IST) and concluded at 01:00 P.M. (IST).

This may kindly be taken on record

Thanking You,

Yours faithfully
For TRANSGENE BIOTEK LIMITED



DR K KOTESWARA RAO
MANAGING DIRECTOR

Encls: as above.

Plot 69 & 70 IDA Bollaram, Sangareddy District – 502 325, Telangana, India
Ph: +91-40-65589499 Fax: +91-8458-279755 Web: www.transgenebiotek.com
Email: info@transgenebiotek.com, CIN No: L85195TG1990PLC011065

Details under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023:

Sr.No	Particulars	Details
1	Reason for change viz. ~~appointment~~, **reappointment**, ~~resignation, removal, death~~ or otherwise	Re-appointment of Dr. K. Koteswara Rao (DIN: 07167872) as Chairman & Managing Director of the Company.
2	Date of ~~appointment / cessation (as applicable)~~ and term of ~~appointment~~ / **re-appointment**	Re-appointed by the Board on 13th November, 2026 with effect from 13th November, 2026
3	Brief profile (in case of appointment).	NIL
4	Disclosure of relationships between directors (in case of appointment of a director)	NIL
5	Information as required pursuant to BSE Circular No. L1ST/COMP/ 14/2018-19 and NSE Circular No. NSE/CMLI20 18124 dated 20th June, 2018	Dr. K. Koteswara Rao is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority

Plot 69 & 70 IDA Bollaram, Sangareddy District – 502 325, Telangana, India
Ph: +91-40-65589499 Fax: +91-8458-279755 Web: www.transgenebiotek.com
Email: info@transgenebiotek.com, CIN No: L85195TG1990PLC011065

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2026

(Rs. In Lakhs, Except EPS)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended (6M)	Year to date figures Previous year ended (6M)	Year Ended
		30-09-2026 (Unaudited)	30-06-2026 (Unaudited)	30-09-2025 (Unaudited)	30-09-2026 (Unaudited)	30-09-2025 (Unaudited)	31.03.2026 (Audited)
1	Revenue from operations	6.00	6.00	5.28	12.00	10.23	21.12
2	Other income (net)	0.00	0.00	0.00	0.00	0.00	14.99
3	**Total income (1 + 2)**	**6.00**	**6.00**	**5.28**	**12.00**	**10.23**	**36.11**
4	**EXPENSES**						
	Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	3.38	3.37	3.31	6.75	8.03	14.73
	Finance costs	28.95	28.95	26.43	57.90	50.98	106.02
	Depreciation and amortisation expense	4.13	4.13	4.98	8.27	9.96	19.91
	Other expenses	4.07	8.45	9.40	12.52	23.47	60.74
	Total expenses	**40.53**	**44.90**	**44.12**	**85.43**	**92.44**	**201.40**
5	**Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)**	**-34.53**	**-38.90**	**-38.84**	**-73.43**	**-82.21**	**-165.29**
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00	**0.00**
7	**Profit before tax (5 - 6)**	**-34.53**	**-38.90**	**-38.84**	**-73.43**	**-82.21**	**-165.29**
8	**Tax expense**						
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
	Total tax expense	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
9	**Profit for the year (7 - 8)**	**-34.53**	**-38.90**	**-38.84**	**-73.43**	**-82.21**	**-165.29**
10	**Other comprehensive income**						
	A Items that will not be reclassified subsequently to profit or loss						
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
11	**Total comprehensive income for the year (9 + 10)**	**-34.53**	**-38.90**	**-38.84**	**-73.43**	**-82.21**	**-165.29**
12	**Earnings per equity share**						
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	-0.05	-0.05	-0.05	-0.10	-0.11	-0.22
	Diluted (Rs.)	(0.05)	(0.05)	(0.05)	(0.10)	(0.11)	(0.22)

Notes:

1	**SECURITIES APPELLATE TRIBUNAL (SAT)**: The matter had come up for hearing on 23rd September 16th October and 29th October 2026 but has not yet come to finality.
2	**APPELLATE TRIBUNAL (ED), NEW DELHI**: The matter had been listed on 2nd November 2026 and adjourned to 12th January 2027.
3	**SBIRI / BIRAC:** We came to know that BIRAC has filed a petition at NCLT Hyderabad bench, claiming for the outstanding interest and the matter said to have come up for hearing on 25th September 2026 followed by notice being served on 5th November 2026 as per the hon'ble Tribunal's direction. Accordingly, the management has taken steps to defend it.
4	**NITIN DIDWANIA**: Having filed an appeal against the order passed on 8th July 2026 directing to pay an amount of Rs. Rs.92,99,250/- with an interest of 6% per annum on the principal amount at the Hon'ble High Court of Bombay Commercial Division, we are waiting for the hearing to commence
5	**CUSTOMS & EXCISE DEPARTMENT**: There has been no further development on this matter since the last board meeting
6	**NCLT :** We are pleased with the dismissal of petition filed by Babaji Netralayya Pvt Ltd against our company by the Hon'ble NCLT Hyderabad on 5th November 2026. However, the management is responding suitably to a notice served on 6th November 2026 on instructions from the same tribunal on the possibility of imposing a penalty under Section 65 of the Code and is preparing to defend it further, if needed.
7	**COMPLAINTS**: No. of complaints pending at the beginning of the quarter – 0; received complaints during the quarter – 0.
8	**AUDIT REVIEW:** The Statutory Auditors of the Company have carried out a Limited Review of the Unaudited Financial Results for the quarter and half-year ended 30th September 2026. The said financial results were reviewed and recommended by the Audit Committee and subsequently considered and approved by the Board of Directors at its meeting held on 13th November 2026.

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 13/11/2026
Place: Hyderabad

TRANSGENE BIOTEK LIMITED

Plot No: 69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN
CIN NO: L85195TG1990PLC011065

(In Lakhs)

Standalone Statement of Assets and Liabilities

PARTICULARS	As at 30 September 2026	As at 31 March 2026
ASSETS		
NON-CURRENT ASSETS		
(a) Property, plant and equipment	301.40	309.30
(b) Right of Use Assets	-	-
(c) Capital work-in-progress	-	-
(d) Investment Properties	-	-
(e) Goodwill	-	-
(f) Other intangible assets	466.67	467.03
(g) Intangible assets under development	186.77	186.77
(h) Biological Assets Other Than Bearer Plants	-	-
(i) Financial assets	-	-
(i) Investments	9.49	9.49
(ii) Trade Receivables	-	-
(iii) Loans	2302.04	2302.04
(iv) Other Financial Assets	-	-
(j) Deferred Tax Assets (Net)	-	-
(k) Other non-current assets	-	-
SUB-TOTAL	**3266.36**	**3274.63**
CURRENT ASSETS		
(a) Inventories	3.40	3.40
(b) Financial assets	-	-
(i) Investments	-	-
(ii) Trade Receivables	-	0.00
(iii) Cash and cash equivalents	5.32	5.32
(iv) Bank Balances other than (iii) above	1.08	0.76
(v) Loans	-	-
(vi) Other Financial Assets	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other current assets	95.16	92.37
SUB-TOTAL	**104.95**	**101.84**
Non-Current Assets Classified as Held for Sale	-	-
TOTAL ASSETS	**3371.31**	**3376.47**

EQUITY AND LIABILITIES	As at 30 September 2026	As at 31 March 2026
EQUITY		
Equity share capital	7577.00	7577.00
Other equity	-8570.41	-8496.98
SUB-TOTAL	**-993.41**	**-919.98**
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Borrowings	721.71	680.08
(ii) Trade Payable	0.00	0.00
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	2302.04	2302.04
(c) Deferred tax liabilities (net)	0.00	0.00
(d) Other non-current liabilities	0.00	0.00
SUB-TOTAL	**3023.76**	**2982.12**
CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	1057.31	1033.60
(ii) Trade payables	7.93	6.83
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	133.09	133.21
(c) Other current liabilities	142.64	140.69
(d) Other Credit Balance	0.00	
(e) Current tax liabilities (net)	0.00	0.00
SUB-TOTAL	**1340.97**	**1314.34**
TOTAL EQUITY AND LIABILITIES	**3371.31**	**3376.47**
Corporate information and significant accounting policies		
The accompanying notes form an integral part of the Consolidated financial statements		

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 13/11/2026
Place: Hyderabad

TRANSGENE BIOTEK LIMITED

Plot No: 69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

Standalone Statement of Cash Flows for the year ended 30th September 2026

(In Lakhs)

Particulars	For the year ended September 30, 2026		For the year ended March 31, 2026	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		-73.43		-165.29
Adjustments for :				
Depreciation and amortisation expense	8.27		19.91	
Finance costs	57.90		106.02	
Amortisation of government grant	0.00		-17.54	
Supplier Advances Written off	0.00		0.00	
Bad debts written off	0.00		0.00	
Profit or loss on sale of Fixed asset	0.00		0.00	
Other Non cash Expenses	0.00		0.00	
Operating profit before working capital changes		**-7.27**		**-56.90**
Changes in working capital:				
Adjustments for (increase) / decrease in operating assets:				
Trade Receivables	0.00		0.00	
Other non-current assets	0.00		1.36	
Other Current assets	-2.79		0.00	
Inventories	0.00		0.00	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	1.11		-152.51	
Provision (CL)	-0.13		-1.61	
Borrowing (CL)	0.00		191.90	
Other financial liabilities	0.00		0.00	
Other current liabilities	1.95		14.07	
Provison (NCL)	0.00		0.00	53.21
Cash generated from operations		**-7.13**		**-3.69**
Net income tax paid		0.00		0.00
Net cash flow from operating activities (A)		**-7.13**		**-3.69**
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances	0.00		0.00	
Investments	0.00		0.00	
Proceeds from sale of fixed assets	0.00		0.00	
Net cash (used in) / flow from investing activities (B)		**0.00**		**0.00**
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares				
Finance costs	-57.90		-106.02	
Proceeds from Borrowings	65.35		600.00	
Payment of Borrowing	0.00		-497.66	
Net cash flow (used in) financing activities (C)		**7.45**		**-3.68**
Net increase in Cash and cash equivalents (A+B+C)		**0.32**		**-7.37**
Cash and cash equivalents at the beginning of the year		6.07		0.77
Effect of exchange differences on translation of foreign		0.00		0.00
currency Cash and cash equivalents		0.00		0.00
Cash and cash equivalents at the end of the year		**6.40**		**-6.60**

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao
Managing Director

Date: 13/11/2026
Place: Hyderabad

TRANSGENE BIOTEK LIMITED

Notes forming part of the Standalone financial statements

Other expenses **(In Rs.)**

Particulars	**For the Period ended on 30th September 2026**
Advertisement	0.13
BSNL Fiber Net	0.02
Business Promotional Expenses	0.03
Conveyanace Charges	0.01
E- Voting Charges	0.09
Directors sitting fee	0.15
Miscllaneous Expenses	0.02
Foreign Investment Limit Monitoring Fees	0.10
Legal and Professional Charges	2.63
Office Expense	0.68
Postage and Courier Charges	0.00
Priting and Stationary	0.00
Rates, Taxes and Duties	0.01
Repairs and maintenance	0.02
Telephone Expenses	0.02
Website & Software Expense	0.16
Total	**4.07**

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 13/11/2026
Place: Hyderabad

TRANSGENE BIOTEK LIMITED

Plot No: 69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2026

(In Rs.)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year to date figures Previous year ended	Year Ended
		30-09-2026 (Unaudited)	30-06-2026 (Unaudited)	30-09-2025 (Unaudited)	30-09-2026 (Unaudited)	30-09-2025 (Unaudited)	31.03.2026 (Audited)
1	Revenue from operations	6.00	6.00	5.28	12.00	10.23	21.12
2	Other income (net)	0.00	0.00	0.00	0.00	0.00	14.99
3	**Total income (1 + 2)**	**6.00**	**6.00**	**5.28**	**12.00**	**10.23**	**36.11**
4	**EXPENSES**						
	Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	3.38	3.37	3.31	6.75	8.03	14.73
	Finance costs	28.95	28.95	26.43	57.90	50.98	106.02
	Depreciation and amortisation expense	4.13	4.13	4.98	8.27	9.96	19.91
	Other expenses	4.07	8.45	9.40	12.52	23.47	60.74
	Total expenses	**40.53**	**44.90**	**44.12**	**85.43**	**92.44**	**201.40**
5	**Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)**	**-34.53**	**-38.90**	**-38.84**	**-73.43**	**-82.21**	**-165.29**
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00	**0.00**
7	**Profit before tax (5 - 6)**	**-34.53**	**-38.90**	**-38.84**	**-73.43**	**-82.21**	**-165.29**
8	**Tax expense**						
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
	Total tax expense	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
9	**Profit for the year (7 - 8)**	**-34.53**	**-38.90**	**-38.84**	**-73.43**	**-82.21**	**-165.29**
10	**Other comprehensive income**						
	A Items that will not be reclassified subsequently to profit or loss						
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
11	**Total comprehensive income for the year (9 + 10)**	**-34.53**	**-38.90**	**-38.84**	**-73.43**	**-82.21**	**-165.29**
12	**Earnings per equity share**						
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	-0.05	-0.05	-0.05	-0.10	-0.11	-0.22
	Diluted (Rs.)	(0.05)	(0.05)	(0.05)	(0.10)	(0.11)	(0.22)

Notes:

1	**SECURITIES APPELLATE TRIBUNAL (SAT):** The matter had come up for hearing on 23rd September 16th October and 29th October 2026 but has not yet come to finality.
2	**APPELLATE TRIBUNAL (ED), NEW DELHI:** The matter had been listed on 2nd November 2026 and adjourned to 12th January 2027.
3	**SBIRI / BIRAC:** We came to know that BIRAC has filed a petition at NCLT Hyderabad bench, claiming for the outstanding interest and the matter said to have come up for hearing on 25th September 2026 followed by notice being served on 5th November 2026 as per the hon'ble Tribunal's direction. Accordingly, the management has taken steps to defend it.
4	**NITIN DIDWANIA**: Having filed an appeal against the order passed on 8th July 2026 directing to pay an amount of Rs. Rs.92,99,250/- with an interest of 6% per annum on the principal amount at the Hon'ble High Court of Bombay Commercial Division, we are waiting for the hearing to commence.
5	**CUSTOMS & EXCISE DEPARTMENT:** There has been no further development on this matter since the last board meeting.
6	**NCLT:** We are pleased with the dismissal of petition filed by Babaji Netralayya Pvt Ltd against our company by the Hon'ble NCLT Hyderabad on 5th November 2026. However, the management is responding suitably to a notice served on 6th November 2026 on instructions from the same tribunal on the possibility of imposing a penalty under Section 65 of the Code and is preparing to defend it further, if needed.
7	**COMPLAINTS**: No. of complaints pending at the beginning of the quarter – 0; received complaints during the quarter – 0.
8	**AUDIT REVIEW:** The Statutory Auditors of the Company have carried out a Limited Review of the Unaudited Financial Results for the quarter and half-year ended 30th September 2026. The said financial results were reviewed and recommended by the Audit Committee and subsequently considered and approved by the Board of Directors at its meeting held on 13th November 2026.

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao
Managing Director

Date: 13/11/2026
Place: Hyderabad

TRANSGENE BIOTEK LIMITED

69 & 70, IDA Bollarum, Sangareddy District - 502325, Telangana

CIN NO: L85195TG1990PLC011065

(In Lakhs)

Consolidated Statement of Assets and Liabilities

PARTICULARS	As at 30 September 2026	As at 31 March 2026
ASSETS		
NON-CURRENT ASSETS		
(a) Property, plant and equipment	301.40	309.30
(b) Right of Use Assets	-	-
(c) Capital work-in-progress	-	-
(d) Investment Properties	-	-
(e) Goodwill	-	-
(f) Other intangible assets	466.67	467.03
(g) Intangible assets under development	186.77	186.77
(h) Biological Assets Other Than Bearer Plants	-	-
(i) Financial assets	-	-
(i) Investments	9.49	9.49
(ii) Trade Receivables	-	-
(iii) Loans	13290.24	13290.24
(iv) Other Financial Assets	-	-
(j) Deferred Tax Assets (Net)	-	-
(k) Other non-current assets	-	-
SUB-TOTAL	**14254.56**	**14262.83**
CURRENT ASSETS		
(a) Inventories	3.40	3.40
(b) Financial assets	-	-
(i) Investments	-	-
(ii) Trade Receivables	84,214.00	0.84
(iii) Cash and cash equivalents	5.32	5.32
(iv) Bank Balances other than (iii) above	1.08	0.76
(v) Loans	-	-
(vi) Other Financial Assets	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other current assets	95.16	92.37
SUB-TOTAL	**105.79**	**102.69**
Non-Current Assets Classified as Held for Sale	**-**	**-**
TOTAL ASSETS	**14360.36**	**14365.51**

EQUITY AND LIABILITIES	As at 30 September 2026	As at 31 March 2026
EQUITY		
Equity share capital	7577.00	7577.00
Other equity	-6812.73	-6739.30
SUB-TOTAL	**764.27**	**837.70**
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Borrowings	721.71	680.08
(ii) Trade Payable	0.00	0.00
(iii) Other financial liabilities	0.00	0.00
(b) Provisions	11522.14	11522.14
(c) Deferred tax liabilities (net)	0.00	0.00
(d) Other non-current liabilities	0.00	0.00
SUB-TOTAL	**12243.85**	**12202.22**
CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	1057.31	1033.60
(ii) Trade payables	7.93	6.83
(iii) Other financial liabilities	11.26	11.26
(b) Provisions	133.09	133.21
(c) Other current liabilities	142.64	140.69
(d) Other Credit Balance	0.00	0.00
(e) Current tax liabilities (net)	0.00	0.00
SUB-TOTAL	**1352.23**	**1325.60**
TOTAL EQUITY AND LIABILITIES	**14360.36**	**14365.51**
Corporate information and significant accounting policies		
The accompanying notes form an integral part of the Consolidated financial statements		

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 13/11/2026
Place: Hyderabad

TRANSGENE BIOTEK LIMITED

CIN NO: L85195TG1990PLC011065


Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

Consolidated Statement of Cash Flows for the year ended 30th September 2026

(In Lakhs)

Particulars	For the year ended September 30, 2026		For the year ended March 31, 2026	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		-73.43		-165.29
Adjustments for :				
Depreciation and amortisation expense	8.27		19.91	
Finance costs	57.90		106.02	
Amortisation of government grant	0.00		-17.54	
Supplier Advances Written off	0.00			
Bad debts written off	0.00			
Profit or loss on sale of Fixed asset	0.00			
Other Non cash Expenses	0.00			
Operating profit before working capital changes		**-7.27**		**-56.90**
Changes in working capital:				
Adjustments for (increase) / decrease in operating assets:				
Trade Receivables	0.00		0.00	
Other non-current assets	0.00		1.36	
Other Current assets	-2.79		0.00	
Inventories	0.00		0.00	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	1.11		-152.51	
Provision (CL)	-0.13		-1.61	
Borrowing (CL)	0.00		191.90	
Other financial liabilities	0.00		0.00	
Other current liabilities	1.95		14.07	
Provison (NCL)	0.00		0.00	53.21
Cash generated from operations		**-7.13**		**-3.69**
Net income tax paid		0.00		0.00
Net cash flow from operating activities (A)		**-7.13**		**-3.69**
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances	0.00		0.00	
Investments	0.00		0.00	
Proceeds from sale of fixed assets	0.00		0.00	
Net cash (used in) / flow from investing activities (B)		**0.00**		**0.00**
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares				
Finance costs	-57.90		-106.02	
Proceeds from Borrowings	65.35		600.00	
Payment of Borrowing	0.00		-497.66	
Net cash flow (used in) financing activities (C)		**7.45**		**-3.68**
Net (decrease) in Cash and cash equivalents (A+B+C)		**0.32**		**-7.37**
Cash and cash equivalents at the beginning of the year		6.07		0.77
Effect of exchange differences on translation of foreign		0.00		0.00
currency Cash and cash equivalents		0.00		0.00
Cash and cash equivalents at the end of the year		**6.40**		**-6.60**

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 13/11/2026
Place: Hyderabad

TRANSGENE BIOTEK LIMITED

Notes forming part of the Consolidated financial statements

Other expenses **(In Rs.)**

Particulars	**For the Period ended on 30th September 2026**
Advertisement	0.13
BSNL Fiber Net	0.02
Business Promotional Expenses	0.03
Conveyanace Charges	0.01
E- Voting Charges	0.09
Miscllaneous Expenses	0.02
Directors Sitting Fee	0.15
Foreign Investment Limit Monitoring Fees	0.10
Legal and Professional Charges	2.63
Office Expense	0.68
Postage and Courier Charges	0.00
Priting and Stationary	0.00
Rates, Taxes and Duties	0.01
Repairs and maintenance	0.02
Telephone Expenses	0.02
Website & Software Expense	0.16
Total	**4.07**

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 13/11/2026
Place: Hyderabad

RANGANATH PRASAD & CO.
CHARTERED ACCOUNTANTS

Block No. 6, 2nd Floor,
Hanfi Complex,
Near Jatpura Gate,
Chandrapur [MH]442401
Mob : 9405900404
mranganath31791@gmail.com

Limited Review Report

To,

The Board of Directors,
M/s TRANSGENE BIOTEK LIMITED
Hyderabad

We have reviewed the accompanying statement of unaudited standalone financial results of M/s TRANSGENE BIOTEK LIMITED for the Quarter ended 30th September 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For RANGANATH PRASAD & CO.
CHARTERED ACCOUNTANTS
FRN: 151856W

RANGANATH PRASAD & CO. CA FRN 151856W CHANDRAPUR

CA M. RANGANATH PRASAD
PARTNER
MRN : 191922

UDIN : 26191922ZOIXKX8936
Place: HYDERABAD
Date: 13.11.2026

RANGANATH PRASAD & CO.
CHARTERED ACCOUNTANTS

Block No. 6, 2nd Floor,
Hanfi Complex,
Near Jatpura Gate,
Chandrapur [MH]442401
Mob : 9405900404
mranganath31791@gmail.com

Independent Auditor's Review Report on consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors,
M/s Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of M/s Transgene Biotek Ltd ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates for the quarter ended 30/09/2026 being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30/09/2026 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

RANGANATH PRASAD & CO. CA FRN 151856W CHANDRAPUR

5. The Statement includes the results of the following entities:

    1. Transgene Biotek HK Ltd – Subsidiary

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We did not review the interim financial results of subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30th September 2026, as considered in the consolidated unaudited financial results.

For RANGANATH PRASAD & CO.
CHARTERED ACCOUNTANTS
FRN 151856W

RANGANATH PRASAD & CO. CA FRN 151856W CHANDRAPUR

CA M. RANGANATH PRASAD
PARTNER
MRN: 191922

UDIN: 26191922ZOIXKX8936
Place: HYDERABAD
Date: 13.11.2026